Literature DB >> 9703908

Intracavitary administration: pharmacokinetic advantages of macromolecular anticancer agents against peritoneal and pleural carcinomatoses.

M Kimura1, T Konno, Y Miyamoto, Y Kojima, H Maeda.   

Abstract

BACKGROUND: Pleural and peritoneal carcinomatoses are quite difficult to control in patients with advanced cancer. We have devised a suitable formulation of anticancer agents to be injected by the intracavitary route.
MATERIALS AND METHODS: The pharmacokinetics of macromolecular anticancer agent, copoly(styrene/maleic acid)-conjugated neocarzinostatin (smancs) and radiolabeled albumin were studied after intraperitoneal administration to ascitic tumor-bearing rats and mice, and were compared with the pharmacokinetics of other low-molecular-weight anticancer agents, mitomycin C (MMC) and doxorubicin (DOX).
RESULTS: Pharmacokinetic analyses indicated that smancs showed a much higher drug concentration for a longer time in the peritoneal cavity, and a much lower drug concentration in the blood circulation than did MMC or DOX. The cavity/blood ratios of the area under the concentration curve (AUC), of smancs, bovine serum albumin (BSA), DOX, and MMC were 9.69, 7.06, 1.38, 1.15, respectively.
CONCLUSION: These results suggest that macromolecular agents are cleared more slowly from the cavitary compartment and remain there at a high concentration while the blood concentration remains low.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9703908

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  2 in total

1.  Preparation of penta-O-galloyl-β-D-glucose from tannic acid and plasma pharmacokinetic analyses by liquid-liquid extraction and reverse-phase HPLC.

Authors:  Li Li; Ahmad Ali Shaik; Jinhui Zhang; Katai Nhkata; Lei Wang; Yong Zhang; Chengguo Xing; Sung-Hoon Kim; Junxuan Lü
Journal:  J Pharm Biomed Anal       Date:  2010-09-29       Impact factor: 3.571

2.  Locoregional immunotherapy of malignant effusion from colorectal cancer using the streptococcal preparation OK-432 plus interleukin-2: induction of autologous tumor-reactive CD4+ Th1 killer lymphocytes.

Authors:  Y Yamaguchi; E Miyahara; A Ohshita; Y Kawabuchi; K Ohta; K Shimizu; K Minami; J Hihara; A Sawamura; T Toge
Journal:  Br J Cancer       Date:  2003-11-17       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.